Female Androgenetic Alopecia: A Survey of Causes and Therapeutic Options

This article discusses the autoimmune causes of alopecia areata and reports no new clinical results.

Minoxidil activation by hair enzymes predicts treatment success for female hair loss.

This article reviews the cellular dynamics affecting dermal papilla size in androgenetic alopecia and suggests targeting DP size could improve therapies, but it presents no new clinical data.

In this study, patients with alopecia areata experienced significant hair regrowth using topical latanoprost, minoxidil, or betamethasone valerate, with the addition of latanoprost enhancing the effectiveness of betamethasone valerate, showcasing these treatments as safe and effective options.

In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.

This study suggests that 2% minoxidil and Kerium may promote hair regrowth in rats, while Aminexil showed the least effect among tested treatments; human-use products varied in efficacy in this animal model.

In this study, mesotherapy using a combination of micronutrients and antioxidants significantly increased hair density in younger women with androgenetic alopecia, with effects lasting 6-12 months, compared to older women.

This review discusses the diagnosis, pathophysiology, growth cycle, and medical treatment of androgenetic alopecia and offers no new clinical results.

This review discusses the potential mechanisms and evidence supporting low-level laser therapy for stimulating hair growth in men and women, while noting its safety and effectiveness but needing further study on specific parameters.

In this study, water-soluble minoxidil promoted hair growth and influenced the hair cycle in a C57BL/6 mouse alopecia model, particularly at a 1.5% concentration.